Kerri Fitzgerald

DocwireNews

The U.S. Food and Drug Administration (FDA) approved Scenesse&reg; (afamelanotide) to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria. This is the first FDA approval for this indication.Erythropoietic protoporphyria is a rare disorder caused by mutations leading to impaired activity of ferrochelatase, an enzyme involved in heme production&mdash;a component in hemoglobin. The decrease in ferrochelatase activity leads to an accumulation of protoporphyrin IX; in these patients, light interaction can result in intense skin pain and skin changes, such as redness and thickening.This melanocortin-1 receptor agonist is a subcutaneous implant that increases the production of eumelanin in the skin independent of exposure to sunlight or artificial light sources.<h2>Afamelanotide increases tolerance of light exposure</h2>The approval was based on two parallel group <a href="https://www.docwirenews.com/docwire-pick/understanding-the-phases-of-clinical-trials/">clinical trials</a> that included patients with erythropoietic protoporphyria who received afamelanotide or a placebo implant subcutaneously every two months. The first <a href="https://www.docwirenews.com/docwire-pick/future-of-medicine-picks/using-ai-to-better-recruit-clinical-trial-participants/">clinical trial</a> included 93 patients, 48 of whom received afamelanotide. Patients were followed for 180 days. The median total number of hours over 180 days spent in direct sunlight between 10 AM and 6 PM on days with no pain (primary endpoint) was 64 hours for patients receiving afamelanotide versus 41 hours for patients receiving placebo.The second clinical trial included 74 patients, 38 of whom received afamelanotide. Patients were followed for 270 days. The median total number of hours over 270 days spent outdoors between 10 AM and 3 PM on days with no pain for which &ldquo;most of the day&rdquo; was spent in direct sunlight (primary endpoint) was six hours for patients receiving afamelanotide versus 0.75 hours for patients receiving placebo.The most common adverse events associated with afamelanotide include implant site reaction, nausea, oropharyngeal pain, cough, fatigue, skin hyperpigmentation, dizziness, melanocytic nevus, respiratory tract infection, somnolence, non-acute porphyria, and skin irritation. Afamelanotide may induce skin darkening, and it is recommended that patients undergo a full body skin examination twice per year. Patients should also maintain sun protection measures during treatment with afamelanotide to prevent phototoxic reactions related to erythropoietic protoporphyria.

BMI Modifies the Relationship Between Glycemic Status and Asthma Severity in Children

Asthma

Jordana Jampel

Cutaneous Melanoma: Sun Protection Behaviors and UV Exposure in Canada

Melanoma

Leah Lawrence

Significant Cardiac Benefit Seen With Ifetroban in Patients With Duchenne Muscular Dystrophy

Neurology

Latest News

FDA Approves Drug for Phototoxic Reactions in Erythropoietic Protoporphyria

Oncology

The U.S. Food and Drug Administration (FDA) approved Scenesse® (afamelanotide) to increase pain-free light exposure in adults with a history of phototoxic reactions from ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe